Skip to main content

Prevalent and Incident Use of Generic Name Kinase Inhibitors

Basic Details
Date Posted
Status
In progress
Medical Product
afatinib dimaleate
axitinib
bortezomib
cabozantinib s-malate
carfilzomib
ceritinib
crizotinib
dabrafenib mesylate
dasatinib
erlotinib HCL
everolimus
gefitinib
ibrutinib
idelalisib
imatinib mesylate
lapatinib ditosylate
nilotinib HCL
pazopanib HCL
ponatinib HCL
regorafenib
ruxolitinib phosphate
sorafenib tosylate
sunitinib malate
trametinib dimethyl sulfoxide
vandetanib
vemurafenib
Description

These reports look at the prevalent and incident use of 27 kinase inhibitors in the Mini-Sentinel Distributed Database (MSDD). These results were generated using the Mini-Sentinel Distributed Query Tool. These queries were run against the Dispensing Summary Table and distributed on November 14, 2014 to 14 Data Partners; these reports include information from 14 Data Partners.

Deliverables (1)
Mini-Sentinel Summary Table Report: Prevalent Use of Generic Name Kinase Inhibitors
Additional Details
FDA Center
CDER
Time Period
2001-2014
Analysis Type
Summary Table
Population / Cohort
All individuals
Data Sources
Mini-Sentinel Distributed Database (MSDD)